October 2012 | OncologyLive

A Man of Many Battles: Genitourinary Expert Spurs Advances Amid Challenges

November 12, 2012

An interview with Nicholas J. Vogelzang, MD, a researcher who has changed the course of cancer treatment by helping to develop therapies for prostate cancer, kidney cancer, bladder cancer, testicular cancer, and mesothelioma.

When Toxicity Counts: It's Time to Reappraise Non-Severe but Clinically Relevant Side Effects

November 02, 2012

As an increasing number of cancers are considered chronic diseases treatable with continuous drug delivery, it is essential that our vocabulary describing the side effects experienced by our patients more appropriately reflects this new paradigm.

Redefining Standard-of-Care: In Rare Cancers, the Experiences of Two Patients May Be Enough

October 24, 2012

As more individual cancers undergo molecular profiling, we can anticipate that the scenario in which a targeted drug demonstrates rather remarkable clinical activity against a rare tumor type will become increasingly common.